Gyre Therapeutics (GYRE) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts GYRE Hot Sheet
Join SI Premium – FREE
Gyre Therapeutics (NASDAQ: GYRE) reported Q3 EPS of $0.03, $0.02 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $30.56 million versus the consensus estimate of $33.55 million.
For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UGI shares spike on reported KKR bid for the company
- Piper Sandler Downgrades Weave Communications Inc (WEAV) to Neutral
- Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
